Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI Study. jkcvhl [Internet]. 2025 Oct. 13 [cited 2025 Oct. 20];12(4):7-18. Available from: https://mail.jkcvhl.com/~jkcvhlco/index.php/jkcvhl/article/view/403